Evidence map›Paper›PMID 39764218›Full record

ReviewEXCLI journal2024

Modulating the p53-MDM2 pathway: the therapeutic potential of natural compounds in cancer treatment.

Iman Ramli, Thamere Cheriet, Anna Maria Posadino, Roberta Giordo, Grazia Fenu, Kingsley Chukwuemeka Nwachukwu, Oluwafemi Adebayo Oyewole, Charles Oluwaseun Adetunji, Daniela Calina, Javad Sharifi-Rad and 1 more

Abstract readReview
In one paragraph

Review in EXCLI journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Uncovering Time-DependentMolecules (Basel, Switzerland) · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Iman RamliLaboratory of Applied Biochemistry, Faculté des Sciences de la Nature et de la Vie, Université Constantine 1 Frères Mentouri, 25000 Constantine, Algeria.
Thamere CherietUnité de Valorisation des Ressources Naturelles, Molécules Bioactives et Analyses Physicochimiques et Biologiques, Université Constantine 1 Frères Mentouri, 25000 Constantine, Algeria.
Anna Maria PosadinoDepartment of Biomedical Sciences, University of Sassari, Viale San Pietro 43B, 07100 Sassari, Italy.
Roberta GiordoDepartment of Biomedical Sciences, University of Sassari, Viale San Pietro 43B, 07100 Sassari, Italy.
Grazia FenuDepartment of Biomedical Sciences, University of Sassari, Viale San Pietro 43B, 07100 Sassari, Italy.
Kingsley Chukwuemeka NwachukwuDepartment of Microbiology, Faculty of Biological Sciences, Abia State University, Uturu, Nigeria.
Oluwafemi Adebayo OyewoleDepartment of Microbiology, Federal University of Technology, Minna, Nigeria.
Charles Oluwaseun AdetunjiLaboratory of Applied Microbiology, Biotechnology and Nanotechnology, Department of Microbiology, Edo State University, Uzairue, Edo State, Nigeria.
Daniela CalinaDepartment of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Javad Sharifi-RadUniversidad Espíritu Santo, Samborondón 092301, Ecuador.
Gianfranco PintusDepartment of Biomedical Sciences, University of Sassari, Viale San Pietro 43B, 07100 Sassari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The p53-MDM2 pathway plays a crucial role regulating tumor suppression and is a focal point of cancer research. This literature review delves into the complex interplay between the tumor suppressor protein p53 and its main regulator MDM2, highlighting their interaction and implications in cancer development and progression. The review compiles and summarizes the existing understanding of the biology and regulation of p53 and MDM2, emphasizing their roles in various cellular processes, including cell cycle regulation, DNA repair, apoptosis, and metabolism. It also discusses the disruption of the p53-MDM2 interaction in different cancer types and its impact on tumor progression and therapeutic resistance. Recent studies have highlighted natural products as promising avenues for targeting the p53-MDM2 pathway. This review categorizes these natural compounds into three groups based on their mechanisms: those that inhibit MDM2 expression or stability, those that prevent p53-MDM2 binding, and those that stabilize p53 by inhibiting MDM2's E3 ligase activity. Detailed mechanisms of action, structural aspects, and potential therapeutic applications of various natural products, including polyphenols, terpenoids, and alkaloids, are presented. Despite significant advances in understanding the p53-MDM2 interaction and the identification of natural products capable of modulating this pathway, further research is necessary to evaluate the clinical efficacy, toxicity, and bioavailability of these compounds. The promising role of natural products in cancer therapy underscores the importance of ongoing investigation and development of these agents as potential treatments for cancer.

Indexed as

cancer therapyMDM2natural productsp53tumor suppression

Identifiers

PMID39764218
PMCPMC11701300

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.